Compare · BDX vs RSLS
BDX vs RSLS
Side-by-side comparison of Becton Dickinson and Company (BDX) and ReShape Lifesciences Inc. (RSLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and RSLS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX carries a market cap of $59.39B.
- BDX has hit the wire 11 times in the past 4 weeks while RSLS has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 1 for RSLS).
- Company
- Becton Dickinson and Company
- ReShape Lifesciences Inc.
- Price
- -
- -
- Market cap
- $59.39B
- -
- 1M return
- +12.51%
- -
- 1Y return
- +45.28%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 1
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
ReShape Lifesciences Inc.
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Latest BDX
- Director Huffines Robert Luther was granted 158 units of Rights to Common Stock Under BD Deferred Compensation Plan (SEC Form 4)
- Director Byington Carrie L was granted 79 units of Rights to Common Stock Under 1996 Directors Deferral Plan (SEC Form 4)
- BD to Host Investor Day on December 10, 2026
- Chairman, CEO and President Polen Thomas E Jr exercised 20,239 shares at a strike of $178.94, returned $3,621,660 worth of shares to the company (17,246 units at $210.00) and sold $628,530 worth of shares (2,993 units at $210.00) as part of a pre-agreed trading plan (SEC Form 4)
- Becton Dickinson upgraded by Wells Fargo with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
- BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
- BD Names Bridget Bagnato Worldwide President of Peripheral Intervention
- BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
Latest RSLS
- ReShape Lifesciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- SEC Form 424B5 filed by ReShape Lifesciences Inc.
- ReShape Lifesciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
- SEC Form 10-Q filed by ReShape Lifesciences Inc.
- Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
- Vyome Announces New Board of Directors with Deep MIT and AI Ties
- ReShape Lifesciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
- SEC Form 425 filed by ReShape Lifesciences Inc.